BIOMARIN PHARMACEUTICAL INC Asset Retirement Obligation, Revision of Estimate
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Asset Retirement Obligation, Revision of Estimate of -$250.00 thousand for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Notes › Asset Retirement Obligations
us-gaap:AssetRetirementObligationRevisionOfEstimate · last filed 2016-11-03
- BIOMARIN PHARMACEUTICAL INC asset retirement obligation, revision of estimate for the quarter ending 2016-09-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC asset retirement obligation, revision of estimate for the quarter ending 2016-06-30 was -$500.00K.
- BIOMARIN PHARMACEUTICAL INC asset retirement obligation, revision of estimate for the quarter ending 2016-03-31 was $250.00K.
| Period end | Asset Retirement Obligation, Revision of Estimate 3 month | Asset Retirement Obligation, Revision of Estimate 6 month | Asset Retirement Obligation, Revision of Estimate 9 month |
|---|---|---|---|
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$500.00K derived: sum of 2 quarters · filed 2016-11-03 | -$250.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$250.00K 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $250.00K 10-Q · filed 2016-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |